Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Beauvechain – page 131

1 944 clinical trials in Beauvechain, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Beauvechain at a glance
1 944
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 944 trials in Beauvechain

Open in trial search

Study on Vudalimab or Pembrolizumab with Chemotherapy for Advanced Non-small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Xencor Inc.

Study of Nacystelyn for Patients with Obstructive Sleep Apnea

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Nacystelyn
  • Sponsor:Laboratoires S.M.B.

Neoplasm malignant

Not recruiting

A Study of GEN1047 in Patients with Solid Tumors: First Time Use in Humans

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:GEN1047
  • Sponsor:Genmab A/S

Study of Durvalumab in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Study comparing darolutamide versus hormone therapy (goserelin, leuprorelin, triptorelin, degarelix) in men with untreated hormone-sensitive prostate cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Study of Selpercatinib for Patients with Early-Stage RET Fusion-Positive Non-Small Cell Lung Cancer After Local Treatment

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Selpercatinib
  • Sponsor:Eli Lilly & Co.

Study of mRNA-4157 and Pembrolizumab for Patients with Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer metastatic+1

Not recruiting

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with Advanced HER2-Positive Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Cervix carcinoma

Not recruiting

Study of Chemoradiotherapy With or Without Pembrolizumab for Patients With High-Risk, Locally Advanced Cervical Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Mantle cell lymphoma

Not recruiting

Study of Zanubrutinib and Rituximab Compared to Bendamustine and Rituximab for Patients with Untreated Mantle Cell Lymphoma Ineligible for Stem Cell Transplant

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:BeOne Medicines AG

Hyperphagia

Not recruiting

Study on Carbetocin Nasal Spray for Reducing Uncontrollable Hunger in Patients with Prader-Willi Syndrome

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Carbetocin
  • Sponsor:Acadia Pharmaceuticals Inc.

Adenocarcinoma gastric+1

Not recruiting

Study of MK-2870 for Patients with Advanced or Metastatic Stomach Cancer, Comparing Its Effects to a Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Beauvechain

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical research focusing on proton pump inhibitor (PPI) medication management strategies in primary care settings. The studies examine optimal approaches for patients with functional dyspepsia and reflux conditions.

  • PPI De-prescribing Strategies
  • Gastrointestinal Health Management
  • Primary Care Interventions

Investigations compare different therapeutic approaches, including on-demand medication use and alternative treatments, to improve long-term patient outcomes in acid-related disorders.

02 Primary Care Medicine

Studies evaluating the effectiveness of various medication discontinuation protocols for patients with chronic heartburn and related conditions. Research aims to establish optimal treatment pathways.

  • Medication Management
  • Patient-Centered Care
  • Treatment Optimization

The research explores alternative therapeutic options and their impact on patient well-being and quality of life.

03 Digestive Health

Clinical investigations examining the management of acid reflux and related conditions through various therapeutic approaches, including traditional and alternative treatment methods.

  • Symptom Management
  • Alternative Therapies
  • Long-term Care Strategies

Research focuses on developing evidence-based approaches for medication reduction while maintaining optimal symptom control.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.